Pezcoller Foundation and American Association for Cancer Research Honor Outstanding Achievements of Dr. Peter K. Vogt
WASHINGTON, D.C. — Peter K. Vogt, Ph.D., will receive the 2013 Pezcoller Foundation-AACR International Award for Cancer Research for his groundbreaking work on cancer-causing viruses that helped establish the field of cancer genetics.
Vogt, the executive vice president for scientific affairs and a professor at The Scripps Research Institute in La Jolla, Calif., will give an award lecture, “PI3K – from simplicity to complexity and back,” during the AACR Annual Meeting 2013 on Monday, April 8 at 5:30 p.m. ET in Ballroom A-B in the Walter E. Washington Convention Center, in Washington, D.C.
The Pezcoller Foundation-AACR International Award, now in its 16th year, recognizes an individual scientist of international renown who has made a major scientific discovery in basic or translational cancer research.
“Dr. Vogt is a preeminent scientist and we are very pleased to recognize his pioneering research on the genetic causes of cancer,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “His work with Rous sarcoma virus established the paradigm of oncogenes as potential inducers of cancer and had a profound impact on the field of cancer research.”
“I am greatly honored and delighted to be chosen as the 2013 recipient of the Pezcoller Foundation-AACR International Award for Cancer Research. I have long admired previous recipients of the Pezcoller Award and am both somewhat intimidated and greatly excited to be joining their ranks,” Vogt said.
Vogt has spent his entire career in cancer research, much of it focused on studying cancer-causing viruses. In 1970, he published his revolutionary work on the genetic basis of the cancer-causing capability of the Rous sarcoma virus. He subsequently made several further pioneering discoveries, including identifying several genes that are important in driving human cancers: myc, jun and PI3K. His more recent studies have shown that cancer-causing mutations in PI3K can render it a specific therapeutic target, and have led to the ongoing clinical development of numerous agents designed to exploit this.
Vogt received his doctorate from the University of Tübingen in Germany, and completed postdoctoral training at the University of California, Berkeley, before becoming associate professor of pathology at the University of Colorado School of Medicine in Denver. He then served as professor of microbiology at the University of Washington School of Medicine in Seattle, and then as the Hastings distinguished professor of microbiology and chairman of the Department of Microbiology at the University of Southern California School of Medicine in Los Angeles before going to The Scripps Research Institute.
Numerous accolades have been awarded to Vogt, including the California Scientist of the Year Award (1975), the Ernst Jung Prize for Medicine (1985), the Robert J. and Claire Pasarow Award (1987), the Bristol Myers Award (1989), the ICN International Prize in Virology (1989), the Charles S. Mott Prize from the General Motors Cancer Research Foundation (1991), the Gregor Johann Mendel Medal from the National Academy of the Sciences of the Czech Republic (2008) and the Albert Szent-Györgyi Prize for Progress in Cancer Research (2010).
Vogt is currently on the editorial boards of several journals, is on the board of directors of the Foundation for Advanced Cancer Studies and the scientific advisory board of the Sidney Kimmel Foundation for Cancer Research, and was elected to the American Academy of Microbiology Board of Governors (2009-2012). He is also a member of many academies and societies, including the AACR, the National Academy of Sciences, the German Academy of Sciences, the Institutes of Medicine and the American Association for the Advancement of Sciences, as well as being an honorary member of the Germany Society of Virology and the Society of Chinese Bioscientists in America.
Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
In Washington, D.C.,
April 6-10, 2013: